Noriko Nishikawa

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson's disease patients.
  2024 L1 100/100

1 assessed by us (1 reproduced) · 5 not yet assessed — every PubMed paper on record, linked below.

• Whole-brain histogram analysis and top 20% gray and white matter ratio of amyloid positron emission tomography: A comparison with the centiloid scale ↗

  Annals of Nuclear Medicine · 2026 · PMID 42149370
  not yet assessed
• Randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of antibiotic faecal microbiota transplantation in patients with Parkinson’s disease (FLORA-PD): a study protocol ↗

  BMJ Open · 2025 · PMID 41120147
  not yet assessed
• 18F-FDG PET-based liver segmentation using deep-learning ↗

  Physical and Engineering Sciences in Medicine · 2025 · PMID 40665198
  not yet assessed
• Elapsed time changes of the brain radiopharmaceutical accumulation of the amyloid PET examination using 18F-flutemetamol ↗

  Annals of Nuclear Medicine · 2025 · PMID 40253573
  not yet assessed
• Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson’s disease patients

  Scientific Data · 2024 · PMID 39406833
  L1 100/100
• Response to letter to editor ‘comment on: Safinamide as adjunctive therapy for Parkinson's disease: A promising option with room for improvement’ ↗

  Journal of the Neurological Sciences · 2024 · PMID 38910056
  not yet assessed